Jagat Adhikari

Dr. Jagat Adhikari

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TDTom Dixon
Tom Dixon
DMDerek MacPherson
Derek MacPherson
BMBarmak Mostofian
Barmak Mostofian
TDTaras Dauzhenka
Taras Dauzhenka
SLSamuel Lotz
Samuel Lotz
JIJesus A. Izaguirre
Jesus A. Izaguirre
Targeted protein degradation (TPD) is a promising approach in drug discovery for degrading proteins implicated in diseases. A key step in this process is the formation of a ternary complex where a heterobifunctional molecule induces proximity of an E3 ligase to a protein of interest (POI), thus facilitating ubiquitin transfer to the POI. In this work, we characterize 3 steps in the TPD process. (1) We simulate the ternary complex formation of SMARCA2 bromodomain and VHL E3 ligase by combining hydrogen-deuterium exchange mass spectrometry with weighted ensemble molecular dynamics (MD). (2) We characterize the conformational heterogeneity of the ternary complex using Hamiltonian replica exchange simulations and small-angle X-ray scattering. (3) We assess the ubiquitination of the POI in the context of the full Cullin-RING Ligase, confirming experimental ubiquitinomics results. Differences in degradation efficiency can be explained by the proximity of lysine residues on the POI relative to ubiquitin.

22 November 2019 in Analytical Chemistry
Verified
Journal Article
Closed access
MZMengru Mira Zhang
Mengru Mira Zhang
BBBrett R. Beno
Brett R. Beno
RHRichard Huang
Richard Huang
JAJagat Adhikari
Jagat Adhikari
EDEkaterina G. Deyanova
Ekaterina G. Deyanova
MGMichael L Gross
Michael L Gross

24 July 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JAJagat Adhikari
Jagat Adhikari
JSJules R. Stephan
Jules R. Stephan
DRDon L. Rempel
Don L. Rempel
ENElizabeth M. Nolan
Elizabeth M. Nolan
MGMichael L Gross
Michael L Gross

16 November 2020 in Journal of Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
JAJagat Adhikari
Jagat Adhikari
HZHaiyan Zhao
Haiyan Zhao
EFEstefania Fernandez
Estefania Fernandez
YHYining Huang
Yining Huang
MDMichael Diamond
Michael Diamond
MGMichael L Gross
Michael L Gross

20 March 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
JAJagat Adhikari
Jagat Adhikari
JHJames Heffernan
James Heffernan
MEMelissa Edeling
Melissa Edeling
EFEstefania Fernandez
Estefania Fernandez
PJPrashant N Jethva
Prashant N Jethva
MGMichael L Gross
Michael L Gross
Japanese encephalitis virus (JEV) remains a global public health concern due to its epidemiological distribution and the existence of multiple strains. Neutralizing antibodies against this infection have shown efficacy in in vivo studies. Thus, elucidation of the epitopes of neutralizing antibodies can aid in the design and development of effective vaccines against different strains of JEV. Here, we describe a combination of native mass spectrometry (native-MS) and hydrogen/deuterium exchange mass spectrometry (HDX-MS) to complete screening of eight mouse monoclonal antibodies (MAbs) against JEV E-DIII to identify epitope regions. Native-MS was used as a first pass to identify the antibodies that formed a complex with the target antigen, and it revealed that seven of the eight monoclonal antibodies underwent binding. Native mass spectra of a MAb (JEV-27) known to be non-binding showed broad native-MS peaks and poor signal, suggesting the protein is a mixture or that there are impurities in the sample. We followed native-MS with HDX-MS to locate the binding sites for several of the complex-forming antibodies. This combination of two mass spectrometry-based approaches should be generally applicable and particularly suitable for screening of antigen–antibody and other protein–protein interactions when other traditional approaches give unclear results or are difficult, unavailable, or need to be validated.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
NBNigel Beaton
Nigel Beaton
JAJagat Adhikari
Jagat Adhikari
RBRoland Bruderer
Roland Bruderer
RTRon Tomlinson
Ron Tomlinson
YFYuehan Feng
Yuehan Feng
LRLukas Reiter
Lukas Reiter
Background: Beyond phenotypic efficacy and safety categorization, high resolution profiling of drug-protein interactions and binding mechanisms remains a major hurdle during lead selection and optimization. A key milestone in structure-based drug design is compound binding site identification and characterization. Structure-activity relationship (SAR) studies utilize techniques such as nuclear magnetic resonance (NMR), x-ray crystallography (X-ray), cryo-electron microscopy (cryo-EM) and the mass spectrometry-based hydrogen-deuterium exchange (HDX) to address these hurdles but they are labor, time and cost intensive. Further, SAR studies are often complicated by protein size (i.e. large proteins) and location (i.e. membrane proteins), which can lead to protocol adaptations (e.g. recombinant protein usage and/or protein truncation) that can introduce artifacts. Using limited proteolysis (LiP) coupled to next-generation mass spectrometry we have developed a high-throughput, high-resolution approach (HR-LiP) that utilizes peptide-level resolution to characterize drug-protein interactions including for proteins that hindered by the previously mentioned limitations. Methods: To boost protein abundance in their native environment, proteins of interest were overexpressed in HEK293 cells using a simple plasmid construct. Cell lysates were incubated with the compounds of interest at increasing concentrations. Samples were then subjected to a limited digest using proteinase K and further processed for data independent acquisition (DIA)-MS analysis using trypsin. Data was analyzed using a directDIA workflow in Spectronaut. Results: Two well-characterized drug target proteins, bromodomain-containing protein 4 (BRD4) and epidermal growth factor receptor (EGFR), were selected for analysis. Using HR-LiP we identify the binding site of the BRD4 inhibitor JQ1 in the full-length protein, which is typically too large to be used directly in with conventional methods. Further, we map the intracellular binding location of both gefitinib and afatinib, two inhibitors of the membrane protein EGFR. Our data for both proteins are in good accordance with orthogonal data obtained by HDX-MS, NMR and X-ray studies. Conclusions: We demonstrate that HR-LiP can be used to dissect small molecule-protein binding events, including compound binding site prediction for protein targets classically considered to be difficult. Given its biological power, broad applicability and ease of implementation, we envision the use of HR-LiP as a routine approach for target validation and lead optimization in small molecule drug discovery pipelines. Citation Format: Nigel Beaton, Jagat Adhikari, Roland Bruderer, Ron Tomlinson, Yuehan Feng, Ivan Cornella-Taracido, Lukas Reiter. Prediction of small molecule-protein binding events for BRD4 and EGFR inhibitors using HR-LiP, a novel structural proteomics approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2136.